NZ710495A - Therapeutic compositions and methods involving mrna transfection - Google Patents

Therapeutic compositions and methods involving mrna transfection

Info

Publication number
NZ710495A
NZ710495A NZ71049514A NZ71049514A NZ710495A NZ 710495 A NZ710495 A NZ 710495A NZ 71049514 A NZ71049514 A NZ 71049514A NZ 71049514 A NZ71049514 A NZ 71049514A NZ 710495 A NZ710495 A NZ 710495A
Authority
NZ
New Zealand
Prior art keywords
polypeptide
mrna
therapeutic compositions
methods involving
cases
Prior art date
Application number
NZ71049514A
Other languages
English (en)
Inventor
Mark C Herzberg
Karen Farnie Ross
Brent S Sorenson
Original Assignee
Mark C Herzberg
Karen Farnie Ross
Brent S Sorenson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mark C Herzberg, Karen Farnie Ross, Brent S Sorenson filed Critical Mark C Herzberg
Publication of NZ710495A publication Critical patent/NZ710495A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ71049514A 2013-01-11 2014-01-10 Therapeutic compositions and methods involving mrna transfection NZ710495A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361751504P 2013-01-11 2013-01-11
PCT/US2014/011041 WO2014110366A1 (en) 2013-01-11 2014-01-10 Therapeutic compositions and methods involving mrna transfection

Publications (1)

Publication Number Publication Date
NZ710495A true NZ710495A (en) 2019-10-25

Family

ID=51167392

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ71049514A NZ710495A (en) 2013-01-11 2014-01-10 Therapeutic compositions and methods involving mrna transfection

Country Status (13)

Country Link
US (3) US20150344537A1 (enExample)
EP (2) EP2943226B1 (enExample)
JP (4) JP2016511230A (enExample)
KR (2) KR102056511B1 (enExample)
CN (1) CN105473163A (enExample)
AU (1) AU2014205298B2 (enExample)
CA (2) CA2901409C (enExample)
ES (1) ES2738315T3 (enExample)
IL (2) IL239898B (enExample)
NZ (1) NZ710495A (enExample)
PL (1) PL2943226T3 (enExample)
SG (2) SG11201505431XA (enExample)
WO (1) WO2014110366A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2943226B1 (en) * 2013-01-11 2019-03-13 Herzberg, Mark C. Therapeutic compositions and methods involving mrna transfection
WO2018083291A1 (en) 2016-11-07 2018-05-11 Westfälische Wilhelms-Universität Münster S100a8/s100a9-induced immunotolerance in newborn subjects
CN107841508A (zh) * 2017-11-29 2018-03-27 重庆市中医院 含抑铁素重组减毒沙门杆菌及构建方法、表达或递送载体
EP3553523A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis
EP3553525A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis
JP6891157B2 (ja) * 2018-11-15 2021-06-18 正生 池本 機能性ペプチド、それを用いた大腸炎用医薬およびデリバリー剤
CN114561381A (zh) * 2022-03-14 2022-05-31 桂林医学院 免疫mRNA及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2797402B1 (fr) * 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
AU7725500A (en) * 1999-09-30 2001-04-30 National Jewish Medical And Research Center Method for inhibition of pathogenic microorganisms
US7754676B2 (en) * 2000-09-15 2010-07-13 The United States Of America As Represented By The Department Of Health And Human Services Defensin-antigen fusion proteins
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
DE10121254A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
WO2004089292A2 (en) * 2003-04-04 2004-10-21 The Regents Of The University Of California Immunomodulatory agents for treatment of inflammatory diseases
DE10324997A1 (de) * 2003-06-03 2004-12-23 Switch Biotech Ag Mrp8/Mrp14 Inhibitoren und ihre Verwendung zur Prävention und/oder Behandlung von hypertrophen Narben und Keloiden
US7927873B2 (en) 2003-12-19 2011-04-19 University Of Cincinnati Polyamides for nucleic acid delivery
US7297786B2 (en) * 2004-07-09 2007-11-20 University Of Iowa Research Foundation RNA interference in respiratory epitheial cells
WO2006078717A2 (en) * 2005-01-19 2006-07-27 Beth Israel Deaconess Medical Center Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis
KR100681763B1 (ko) * 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
US8501478B2 (en) 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
EP2167653A2 (en) * 2007-06-11 2010-03-31 University Of Vermont And State Agricultural College Treatments involving glutaredoxins and similar agents
US8916163B1 (en) * 2007-12-21 2014-12-23 Vanderbilt University Method for treating microbial infections
DE102010040153A1 (de) * 2010-09-02 2012-03-08 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Stoffkombination zur Behandlung von entzündlichen oder infektiösen Erkrankungen
DE12722942T1 (de) * 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US10174081B2 (en) * 2011-04-21 2019-01-08 George Mason Research Foundation, Inc. Antimicrobial peptides and uses therefore
EP2943226B1 (en) * 2013-01-11 2019-03-13 Herzberg, Mark C. Therapeutic compositions and methods involving mrna transfection

Also Published As

Publication number Publication date
AU2014205298B2 (en) 2018-11-01
US20150344537A1 (en) 2015-12-03
KR20160031999A (ko) 2016-03-23
JP6473729B2 (ja) 2019-02-20
IL239898A0 (en) 2015-08-31
EP2943226A1 (en) 2015-11-18
CA2901409C (en) 2022-06-07
JP2019031521A (ja) 2019-02-28
AU2014205298A1 (en) 2015-08-13
US11912744B2 (en) 2024-02-27
KR102119985B1 (ko) 2020-06-05
EP2943226B1 (en) 2019-03-13
EP3501551A1 (en) 2019-06-26
US20200231640A1 (en) 2020-07-23
IL262252B (en) 2020-06-30
PL2943226T3 (pl) 2019-09-30
SG10201603946PA (en) 2016-07-28
JP2016511230A (ja) 2016-04-14
KR20180026811A (ko) 2018-03-13
US20240166701A1 (en) 2024-05-23
JP6956059B2 (ja) 2021-10-27
CN105473163A (zh) 2016-04-06
EP3501551B1 (en) 2023-06-07
US12448421B2 (en) 2025-10-21
SG11201505431XA (en) 2015-08-28
ES2738315T3 (es) 2020-01-21
JP2021019644A (ja) 2021-02-18
WO2014110366A1 (en) 2014-07-17
EP2943226A4 (en) 2016-11-23
JP2017052781A (ja) 2017-03-16
IL262252A (en) 2018-11-29
IL239898B (en) 2018-10-31
CA3152721A1 (en) 2014-07-17
CA2901409A1 (en) 2014-07-17
EP3501551C0 (en) 2023-06-07
KR102056511B1 (ko) 2019-12-16

Similar Documents

Publication Publication Date Title
NZ710495A (en) Therapeutic compositions and methods involving mrna transfection
MX2023013342A (es) Celulas que expresan el receptor de antigeno quimerico (car) con funcion o expresion de tet reducida y metodos de uso de las mismas.
EP3693034B8 (en) Systems for the treatment of wounds with dressing having closed cells
ZA201902247B (en) Anti¿c1s antibodies and methods of use thereof
EP3248110A4 (en) Methods and systems for determining proportions of distinct cell subsets
IN2014CN02527A (enExample)
WO2015185875A9 (fr) Anticorps dirigé contre la galectine 9 et inhibiteur de l'activité suppressive des lymphocytes t régulateurs
WO2016065349A8 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
MX2021002455A (es) Metodos para tratar tumores de celulas epitelioides.
MX2015017045A (es) Inhibidores de bromodominio biciclicos novedosos.
MX2015015512A (es) Arilquinazolinas.
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
NZ727701A (en) Platinum compounds, compositions, and uses thereof
BR112015020290A2 (pt) métodos para tratar um câncer, para prevenir câncer, para inibir proliferação, para tratar terapeuticamente um mamífero, para tratar uma disfunção, para reduzir níveis de proteína spp1, para tratar terapeuticamente um câncer, para tratar um indivíduo e para inibir proliferação celular, artigo, anticorpos e usos
HK1214618A1 (zh) 含有透明質酸的穩定化組合物
EP3268022A4 (en) Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
WO2017044855A3 (en) Cell penetrating peptides that inhibit irf5 nuclear localization
IN2015DN00344A (enExample)
WO2016197024A3 (en) Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl)
WO2018089901A3 (en) Exosome delivery system
MX2015008726A (es) Deteccion fenotipica intracelular.
EA031679B9 (ru) Производные тетрагидрохинолина в качестве ингибиторов бромодомена
EP3186826A4 (en) System for measuring levels of radiation reflecting from semiconductor material for use in measuring the dopant content thereof
EP3180030A4 (en) Trehalose hydrogels for stabilization and delivery of proteins
EP3129092A4 (en) Systems and methods for high concentration nitric oxide delivery

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: THERAPEUTIC COMPOSITIONS AND METHODS INVOLVING MRNA TRANSFECTION; FILING DATE: 28 JUL 2015; STATUS: REJECTED; KIND CODE: A1 PUBLICATION DATE: 31 JUL 2015; TITLE: THERAPEUTIC COMPOSITIONS AND METHODS INVOLVING MRNA TRANSFECTION; FILING DATE: 28 JUL 2015; STATUS: REJECTED; KIND CODE: TITLE: THERAPEUTIC COMPOSITIONS AND METHODS INVOLVING MRNA TRANSFECTION; FILING DATE: 25 JAN 2019; STATUS: PROPOSED; KIND CODE:

Effective date: 20190125

ERR Error or correction

Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: THERAPEUTIC COMPOSITIONS AND METHODS INVOLVING MRNA TRANSFECTION; FILING DATE: 28 JUL 2015; STATUS: REJECTED; KIND CODE: A1 PUBLICATION DATE: 31 JUL 2015; TITLE: THERAPEUTIC COMPOSITIONS AND METHODS INVOLVING MRNA TRANSFECTION; FILING DATE: 28 JUL 2015; STATUS: REJECTED; KIND CODE: TITLE: THERAPEUTIC COMPOSITIONS AND METHODS INVOLVING MRNA TRANSFECTION; FILING DATE: 25 JAN 2019; STATUS: REJECTED; KIND CODE: TITLE: THERAPEUTIC COMPOSITIONS AND METHODS INVOLVING MRNA TRANSFECTION; FILING DATE: 13 MAR 2019; STATUS: PROPOSED; KIND CODE: TITLE: THERAPEUTIC COMPOSITIONS AND METHODS INVOLVING MRNA TRANSFECTION; FILING DATE: 09 MAR 2019; STATUS: REJECTED; KI

Effective date: 20190326

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2022 BY COMPUTER PACKAGES INC

Effective date: 20201218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2023 BY COMPUTER PACKAGES INC

Effective date: 20211217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2024 BY COMPUTER PACKAGES INC

Effective date: 20230117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2025 BY COMPUTER PACKAGES INC

Effective date: 20231230

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JAN 2026 BY COMPUTER PACKAGES INC

Effective date: 20250117